MCL1 and spindle cell hemangioma: Inhibiting Mcl-1, ERK, and JAK1/2 using the three-drug combination resulted in decreased levels of p-ERK (similar to SCH plus AZD5991), p-STAT5 (similar to AZD1480 alone), and c-Myc (similar to SCH plus AZD1480).